Circulating tumor cells: Towards mechanical phenotyping of metastasis

Marina Peralta,1,2,3,4 Naël Osmani,1,2,3,4,* and Jacky G. Goetz1,2,3,4,*

SUMMARY
During cancer progression, metastatic dissemination accounts for ~90% of death in patients. Metastasis occurs upon dissemination of circulating tumor cells (CTC) through body fluids, in particular the bloodstream, and several key steps remain elusive. Although the majority of CTCs travel as single cells, they can form clusters either with themselves (homoclusters) or with other circulating cells (heteroclusters) and thereby increase their metastatic potential. In addition, cancer cell mechanics and mechanical cues from the microenvironment are important factors during metastatic progression. Recent progress in intravital imaging technologies, biophysical methods, and microfluidic-based isolation of CTCs allow now to probe mechanics at single cell resolution while shedding light on key steps of the hematogenous metastatic cascade. In this review, we discuss the importance of CTC mechanics and their correlation with metastatic success and how such development could lead to the identification of therapeutically relevant targets.

INTRODUCTION
The metastatic cascade culminates with cancer cells leaving the primary tumor via body fluids, on their way to vital organs. A plethora of studies now suggest that disseminating tumor cells build on preexisting pre-metastatic niches, which are also under the control of the primary tumor and its ability to secrete pro-metastatic cues, including extracellular vesicles (extensively reviewed by (Ghoroghi et al., 2021)). Upon entering the blood or the lymphatic vasculature, cancer cells become circulating tumor cells (CTCs) (Follain et al., 2020; Lambert et al., 2017) and thereby are subjected to several microenvironmental cues that shape their ability to colonize distant organs. Although metastasis evolves through a series of consecutive steps, tumor cells disseminate very early, even before the primary tumor is fully detectable (Harper et al., 2016; Hosseini et al., 2016; Hu and Curtis, 2020; Husemann et al., 2008; Nagrath et al., 2007; Rhim et al., 2012). Accordingly, recent large-scale genomics data from paired primary tumors and metastases revealed low genomic divergence suggesting that metastases commonly derive from a major clone in the primary tumor several years before diagnosis (Hu and Curtis, 2020). Furthermore, CTCs can colonize their tumors of origin in a process known as “tumor self-seeding” (Kim et al., 2009; Lambert et al., 2017). Hence, a holistic approach is being adopted to better understand its complexity (Suhail et al., 2019).

The genomic contribution to tumorigenesis has been well characterized using global “omics” approaches and the influence of the cellular environment on metastatic progression is well established. The biomechanical properties of the tumor and its microenvironments are also important factors in cancer progression (Gensbittel et al., 2021). More recently, the mechanics of body fluids, of CTCs themselves and of other blood or lymph components have proven to be essential for different processes toward the successful secondary tumor seeding (Follain et al., 2020; Gensbittel et al., 2021).

While growing, tumors need oxygen, nutrients, and a way to drain the interstitial fluid, which lead to tumor vascularization through angiogenesis and lymphangiogenesis (Weis and Cheresh, 2011). Cancer cells enter either blood or lymphatics vessels (Aceto et al., 2014; Giampieni et al., 2009) by co-opting resident cells (Pignatelli et al., 2016). The vascular and lymphatic systems present different biophysical properties. Their flow profiles, circulating cells densities, and fluid shear stress (FSS) (i.e., stress generated when a fluid flow moves tangentially to a surface creating deformation in the flow direction) vary among arteries, veins, capillaries, and lymphatics vessels (extensively reviewed by (Follain et al., 2020)). Such fluidic properties have profound impacts on the fate of CTCs. While the high flow velocity and FSS in arteries cause CTCs to face...
physical damage leading to cell fragmentation and death (Headley et al., 2016; Regmi et al., 2017), reduced flow profiles in veins favor CTCs intravascular arrest and extravasation (Follain et al., 2018, 2021; Osmani et al., 2019). The lower flow velocity and FSS in lymphatic compared to blood vessels (Dixon et al., 2006) might be less deleterious to CTCs. Interestingly, hematogenous and lymphatic metastasis are not mutually exclusive, after lymph node colonization, a sign of poor prognosis, CTCs can travel to blood vessels (Brown et al., 2018; Pereira et al., 2018).

As patient’s blood can be easily collected, liquid biopsies have emerged as a powerful noninvasive tool for prognosis, treatment selection, and monitoring in several cancer types (Keller and Pantel, 2019) (Figures 1A and 1C). Although more work is needed to understand how CTCs mechanics shape tumor metastasis, we and others have proposed that mechanical profiling of CTCs might be relevant as a prognosis biomarker (Alibert et al., 2017; Genstbittel et al., 2021). Thus, a better understanding of CTCs mechanical properties, and the interactions likely to perturb them, will contribute to improve detection accuracy and personalize therapeutic targets design.

In this review, we first detail CTCs characteristics and specificities. We further discuss their ability to form clusters through homo-interactions or with other cell types enhancing their metastatic potential. We finally discuss how such interactions are likely to tune the biomechanical properties of CTCs and their metastatic success. We complement such description with a careful review of some microfluidic platforms that exploit such properties for isolating CTCs and discuss their potential when designing precision medicine strategies.
CTCs in transit: Characteristics, metastatic potential, and isolation methods

Cancer cell dissemination starts as cancer cells acquire invasive potential promoting their escape from the primary tumor (Hanahan and Weinberg, 2011). Epithelial to mesenchymal transition (EMT) of tumor cells, the transdifferentiation process in which cells lose their epithelial characteristics and acquire mesenchymal ones, within the primary site is thought to be a major driver of cancer cell dissemination and thus the generation of CTCs (Caramelo et al., 2013). Upon entering the vasculature, and despite disseminating efficiently from the primary tumor (Al-Hajj et al., 2003) (Figure 1B), the number of CTCs forming secondary tumors is very low due to several limiting factors (Cameron et al., 2000). Most of CTCs will die because of hemodynamic forces inducing apoptosis (Headley et al., 2016; Regmi et al., 2017), anoikis (owing to the loss of integrin-mediated adhesion to the extracellular matrix (ECM)) (Kim et al., 2012) or attacked by the immune system (Chen and Mellman, 2017). Surviving CTCs exit the vasculature (extravasate) either by squeezing through endothelial cells (diapedesis) or by co-opting the endothelium (Follain et al., 2018). Estimations suggest that roughly 0.01% of extravasated CTCs invading distant organs effectively form new colonies implying that most of the cells might eventually enter dormancy or die in their new environment (Chambers et al., 2002; Lambert et al., 2017; Luzzi et al., 1998). Interestingly, EMT and WNT signaling upregulation lead to CTCs anoikis resistance improving their survival (Kim et al., 2012; Yu et al., 2012). In addition, mesenchymal to epithelial transition (MET) takes place upon arrival at the secondary site (Beerling et al., 2016; Ocaña et al., 2012; Tsi et al., 2012) suggesting that the plasticity between these two states is a major driver of metastasis success (Beerling et al., 2016; Pastushenko et al., 2018). Recent studies using single-cell lineage tracing of metastatic cancer cells data, including CTCs, support the latter idea. All the cells analyzed occupied a continuum of EMT states and the highest metastatic potential corresponded with hybrid EMT states (Simeonov et al., 2021; Yu et al., 2013). Subsequently, CTC populations are heterogeneous and gene expression levels vary from cell to cell even within the same patient sample (Pixberg et al., 2017; Powell et al., 2012). The CTC subpopulations able to seed secondary tumors are known as metastasis-initiating cells (MICs) or tumor initiating cells (TICs) (Al-Hajj et al., 2003; Baccelli et al., 2013; Ye et al., 2015). Whether they display cancer stem cell (CSC)-like properties or have a regenerative phenotype remains to be elucidated (Ganesh and Massagué, 2021). However, there is consensus regarding CTCs showing hybrid EMT states linked with both adverse disease outcome and drug resistance (Lambert and Weinberg, 2021).

Microfluidic isolation of CTCs

Currently, there are numerous approaches used for CTC isolation that can be broadly divided into two groups (extensively reviewed in (Bankó et al., 2019) and (Lei, 2020)): 1. Biological properties-based (e.g., marker expression) and 2. Physical properties-based (e.g., size/deformability). Belonging to the first group, the CellSearch system is the only FDA-approved device and relies heavily on the expression of epithelial markers such as epithelial cell adhesion molecule (EpCAM) and cytokeratins (Cristofanilli et al., 2004). The advent of microfabrication has led to the appearance of microdevices with precisely controlled flow parameters. It is thus not surprising that CTCs isolation methods were developed using elegant microfluidic-based technologies. One example is the microfluidic-based CTC-chip, which captures CTCs interacting with EpCAM-coated microposts under controlled laminar flow conditions (Nagrath et al., 2007) (Figure 1D). Microfluidic devices contain structures that are comparable to the cell length scale, such as microposts, and allow for the precise control over sample flow increasing the time for cell-antibody contact, thus improving cell capture efficiency. To improve the outcome of CTC-chip, the herringbone-chip (HB-Chip) generates microvortices to increase the interactions between CTCs and the antibody-coated chip surface (Stott et al., 2010). Finally, microfluidic devices also are used to improve the sensitivity and throughput of EpCAM CTC isolation in devices such as the CTC-iChip (Mishra et al., 2020; Ozkumur et al., 2013). The GILUPI Cell Collector, an innovative in vivo approach, uses a medical wire functionalized with anti-EpCAM antibodies inserted into the cubital vein of patients overcoming blood volume limitations present in other CTCs isolation assays (Saucedo-Zeni et al., 2012). However, these isolation methods have led to a selection bias, losing valuable information from CTCs presenting hybrid EMT state markers. Nowadays, new markers such as the actin bundling protein Plastin-3 and the oncofetal chondroitin sulfate which are expressed on epithelial, mesenchymal, and hybrid EMT states CTCs, are being used to refine the detection methods and will play a key role to determine the association between CTCs EMT status and clinical outcome (Agerbaek et al., 2018; Alix-Panabières et al., 2005; Ueo et al., 2015; Yokobori et al., 2013). The second group bypasses the EMT bias relying on biophysical properties of CTCs compared to other blood components (Alibert et al., 2017; Xin et al., 2019). An example is the Parsortix device, a microfluidic based technology that captures CTCs based on physical properties taking advantage of CTCs being bigger and less compressible than other blood cells (Miller et al., 2018; Xu et al., 2015). Other examples of high-
Better and stronger together: When CTCs travel as homo-clusters

Despite being rarer than single CTCs, groups of two or more CTCs known as CTC clusters show higher metastatic potential and relate to worse outcomes in several cancer types (Aceto et al., 2014; Jansson et al., 2016). Lately, the idea of metastasis arising only from single CTCs was challenged by several genomic and intravital imaging studies revealing that metastatic colonies are composed of multiple genetically distinct clones and that polyclonal collective invasion is highly efficient at initiating the early steps of metastasis (Casasent et al., 2018; Cheung et al., 2016). It was thought that CTC clusters were too big to circulate through capillaries to reach distant organs; therefore, arresting fast and leading to the rupture of vessel walls (Wong et al., 2002). However, an innovative microfluidic-based approach designed to mimic human capillary constrictions revealed that clusters are able to pass through narrow capillaries by unfolding into single-file chains which might explain their increased metastatic potential (Au et al., 2016).

Classically, CTC clusters were described as deriving from oligoclonal tumor cell groupings instead of from intravascular aggregation events in breast cancer (Aceto et al., 2014). Recent studies provided molecular basis for CTC cluster formation, before or after intravasation, involving cell adhesion molecules such as CD44 and ICAM-1 (Liu et al., 2019; Taftaf et al., 2021). In addition, the EMT transcription factor Snail induces the expression of Claudin 11 (tight junctional protein) prompting cluster formation in squamous cell carcinoma (Li et al., 2019). Moreover, breast CTC clusters generated in vitro show Heparanase induced FAK- and ICAM-1-dependent cell adhesion promoting cell aggregation (Wei et al., 2018). CTCs within the clusters display stable Plakoglobin-dependent, Keratin 14-dependent, and E-cadherin-dependent cell adhesions while traveling in the blood (Aceto et al., 2014; Cheung et al., 2016; Padmanaban et al., 2019) suggesting some of these clusters might retain at least partial epithelial identity. CTCs within the clusters show hybrid EMT states (Pastushenko et al., 2018), with a majority displaying mesenchymal markers (Yu et al., 2013).

Several differences between single CTCs and clusters have been described as responsible for the increased metastatic potential of the clusters. First, although subpopulations of single CTCs are apoptotic or proliferative, neither are observed in CTC clusters implicating anoikis protection, stemness, and higher resistance to cytotoxic drugs (Aceto et al., 2014; Gkountela et al., 2019; Hou et al., 2012; Liu et al., 2019; Taftaf et al., 2021). At the molecular level, anoikis resistance was linked to the higher expression of plakoglobin and Bcl2 (anti-apoptotic) in CTC clusters (Huang et al., 2019; Thangavel et al., 2019). Second, while single CTCs show damaged mitochondria that produce increased reactive oxygen species (ROS) inducing apoptosis, CTCs within clusters switch their cellular metabolism to glycolysis and clear damaged mitochondria limiting ROS and increasing metastatic capacity in vitro (Labuschagne et al., 2019). Third, binding sites for stemness- and proliferation-associated transcription factors are hypomethylated in CTC clusters promoting stemness and thus enhancing metastatic success (Gkountela et al., 2019).

On the same line, disaggregation of CTC clusters using several approaches such as CD44 depletion, plakoglobin knockdown, urokinase-type plasminogen activator (thrombolytic agent) injections, and Na⁺/K⁺-ATPase inhibitors treatment, leads to reduced metastatic potential (Aceto et al., 2014; Choi et al., 2015; Gkountela et al., 2019; Labuschagne et al., 2019; Liu et al., 2019).

Microfluidic isolation of homo-clusters of CTCs

Currently, there are several approaches used for CTC cluster isolation, some like the CellSearch device were designed to capture single CTCs, but can be used to isolate clusters (Hou et al., 2012; Paoletti et al., 2019), although may not fully preserve their integrity and miss clusters presenting hybrid EMT state markers. The Cluster-Chip method provides a more tailored isolation technique, where CTC clusters are captured in specialized bifurcating traps under low-FSS conditions that preserve their integrity (Aceto et al., 2014; Sarioglu et al., 2015). Recently, the Parsortix microfluidic device has shown high efficiency...
isolating CTC clusters (99.3% capture rate) avoiding artificial cluster formation because of sample processing (Gkountela et al., 2019) (Figure 1D).

**Looking for allies: Interaction of CTCs with other blood components**

The blood and lymph microenvironment are complex fluidic ecosystems composed of multiple cell types, soluble and encapsulated factors (i.e., extracellular vesicles). The interaction between CTCs and other cell types is pivotal for their metastatic success (Heeke et al., 2019; San Juan et al., 2019) (Figure 1B).

Among the cell types interacting with CTCs are cancer associated fibroblasts (CAFs), which derive from the stroma of the primary tumor and facilitate metastasis (Ao et al., 2015; Ortiz-Otero et al., 2020). CAFs drastically remodel the tumor microenvironment secreting cytokine, chemokines, and growth factors that promote angiogenesis, cancer cells migration, and the evasion of the immune system increasing CTCs viability (Monteran and Erez, 2019).

CTCs also associate with neutrophils enhancing their metastatic potential (Tao et al., 2016). An increase in the neutrophil-to-lymphocyte ratio had been established as a sign of poor prognosis in solid tumors (Templeton et al., 2016); however, the mechanistic explanation behind was unclear. It was recently shown that CTC-neutrophils association leads to the activation of the genetic programs promoting cell cycle progression and providing a likely mechanistic explanation for the enhancement of their metastatic potential (Szczerba et al., 2019). In addition, neutrophils inhibit natural killer (NK) (cytotoxic lymphocytes) function protecting CTCs (Spiegel et al., 2016). Neutrophils can trap CTCs releasing neutrophil extracellular traps (NETs), extracellular DNA webs released in response to inflammatory cues. This interaction relies on the β1-integrin expression in both cell types and can awaken dormant cancer cells leading to metastasis formation (Cools-Lartigue et al., 2013). Interestingly, CTCs attach to arrested neutrophils, use them as a bridge to bind endothelial cells in the liver promoting metastasis (Spicer et al., 2012). The development of in vitro microvascular networks (Chen et al., 2013), as part of the novel organ-on-a-chip devices, allows high-resolution time-lapse microscopy to better understand CTCs extravasation mechanisms. Organ-on-a-chip devices consist of microfluidic channels used as scaffolds for organ-specific cells where external artificial cues including biomechanical forces can be applied to mimic the biochemical and biophysical microenvironment of living organs. A combination of in vivo (mouse) and in vitro (microvascular networks) imaging revealed that neutrophils facilitate CTCs extravasation secreting IL1β and matrix metalloproteinases (Spiegel et al., 2016). Besides, the endothelial glycocalyx can immobilize inflamed neutrophils by self-secreted IL-8 and tumor-derived CXCL-1, leading to neutrophils sequestration with arrested tumor cells and increasing the extravasation potential of the CTCs (Chen et al., 2018).

CTCs can also bind platelets, increasing their metastatic potential (San Juan et al., 2019) and favoring immune evasion by shielding CTCs from NK immunosurveillance (Palumbo et al., 2005). While NK eliminates targets with low expression of major histocompatibility complex (MHC) class I, CTCs coated with platelets displaying high expression of platelet-derived normal MHC class I are spared (Placke et al., 2012). The cross-talk between CTCs and platelets not only modify the tumoral cells, platelets can take up circulating mRNA from CTCs becoming tumor-educated platelets (TEPs) modifying their transcriptome profile (Best et al., 2015). The interaction between CTCs and platelets lead to platelet activation and release of mediators that modify the behavior of the CTCs and surrounding cells (Labelle et al., 2011; Schumacher et al., 2013; Ward et al., 2018). Platelet-derived TGFβ and direct CTC-platelet contact induce EMT in CTCs via TGFβ-Smad and NF-kB pathways activation promoting metastasis. Ablation of platelet-derived TGFβ and NF-kB inhibition in CTCs reduced metastatic success (Labelle et al., 2011). Recently, a direct interaction between platelets and the adhesion G protein-coupled receptor (GPCR) CD97 leading to platelets activation has been uncovered. This interaction leads to granule secretion, including ATP release (Ward et al., 2018) which acts through P2Y2 receptors on endothelial cells rendering the endothelium more permeable thus facilitating CTCs extravasation. Both P2Y2 receptors ablation and ATP release blockade strongly reduce metastasis (Schumacher et al., 2013). Another known interaction occurs between α6β1-integrin on platelets and ADAM9 on CTCs (Mamnadova-Bach et al., 2016). A different advantage of CTCs binding platelets is the activation of YAP1 signaling reducing anoikis (Haemmerle et al., 2017). Papa and colleagues developed human modified platelets (platelet decoys) incapable of functional activation and aggregation. Taking advantage of a microfluidic human microvasculature-on-a-chip device, decoys were revealed to interfere with platelet-mediated human breast cancer cell aggregation decreasing CTCs arrest and extravasation (Papa et al., 2019).
Intravital imaging suggested that tumor-associated macrophages (TAMs) proximity to invading tumor cells is essential during intravasation preceding bloodborne dissemination (Harney et al., 2015). TAMs also play a role in immunosurveillance suppression (Gast et al., 2018; Zhang et al., 2017). CTCs and macrophages can fuse creating hybrid cells harboring epithelial/tumoral and hematopoietic properties (Gast et al., 2018). These cells are found in the peripheral blood of patients with several cancer types and correlates with bad prognosis and enhanced metastatic potential (Gast et al., 2018; Zhang et al., 2017). In addition, TAMs secrete interleukin 6 (IL6) that promote EMT increasing mesenchymal CTC ratio and inhibit the tumor suppressor miR-506-3p. This inhibition indirectly results in chemokine ligand 2 (CCL2) production that promotes macrophage recruitment. Blockage of IL6 or CCL2 broke this loop reducing mesenchymal CTCs number and macrophage migration, respectively (Wei et al., 2019).

Microfluidic isolation of CTC hetero-clusters
Isolation of CTC hetero-clusters is a challenging task. In particular, platelets-coated CTCs are extremely difficult to trap because of masking or downregulation of surface epitopes. However, recent advances in microfluidics devices allowed the design of an efficient approach to trap platelets-coated CTCs using platelets as a ubiquitous cell-surface marker. This two-steps microfluidic strategy first depletes free platelets by size, second isolates platelets-coated CTCs using the herringbone CTC chip which induces microvortices. Moreover, this method has proven efficient to capture CTC-leukocyte clusters (Jiang et al., 2017; Stott et al., 2010). Another microfluidic-based method that has been efficiently used to isolated hetero clusters, specifically CTC-neutrophils, is the Parsortix device (Szczerba et al., 2019) (Figure 1D).

Mechanoadaptation: CTCs force their way to metastasis
Mechanical cues have a broad impact on cancer progression (Kumar and Weaver, 2009) from tumor growth and vascularization to invasion and metastasis dissemination through body fluids. Indeed, during their hematogenous journey CTCs experience considerable levels of FSS (Follain et al., 2020) that are deleterious for the majority of them (Regmi et al., 2017; Xin et al., 2019). Interestingly, using a microfluidic circulatory device mimicking the FSS achievable during intense exercise, Regmi and colleagues show an increase in breast CTCs destruction. Cell death occurred through necrosis within 4 h of flow and by apoptosis between 16 and 24 h of flow (Regmi et al., 2017). One mechanism promoting FSS-induced apoptosis is mediated by the tumor necrosis factor apoptosis-inducing ligand (TRAIL) which binds to death receptors expressed on the surface of CTCs in a force-dependent and time-dependent manner (Mitchell and King, 2013). To unravel whether clusters behave similarly to single CTCs under FSS, Marella and colleagues developed a multi-channel microfluidic device able to reproduce different FSS characterizing the human circulatory system (capillaries, veins, and arteries) that showed clusters disaggregation under high FSS (Marella et al., 2021).

In vitro work suggested that CTCs are more resistant to FSS than expected because of a transient response triggered by plasma membrane damage that relies on extracellular calcium and actin cytoskeletal dynamics (Barnes et al., 2012). The ability to repair plasma membrane damages caused by FSS and the maintenance of their nuclear integrity via Lamin A/C are essential for CTCs survival (Mitchell et al., 2015). Furthermore, FSS prompts cytoskeletal mechanoadaptation that mediates plasma membrane reparations (Moose et al., 2020) and activated the fluid mechanosensor atonal bHLH transcription factor 8 (ATOH8) which promoted glycolysis-dependent CTC survival (Huang et al., 2020). Similarly, CTC clusters under FSS develop their own survival strategies like the generation of stable cell aggregates resistant to anoikis in an E-cadherin-dependent manner. Interestingly, CTCs clusters are also able to regulate their cortical actin-myosin dynamic achieving higher stability under FSS (Maeshiro et al., 2021). Hetero-cluster formed between CTCs and CAFs enhance FSS resistance via intercellular contact and soluble derived factors. Moreover, CAFs conserve the proliferative capability of CTCs subjected to high FSS (Ortiz-Otero et al., 2020). Likewise, platelets shield platelets-coated CTCs from FSS-derived damage (Labelle et al., 2011). Of note, FSS seems to regulate the kinetics and molecular mechanisms of platelets binding CTCs, low FSS revealed higher adhesion efficiency (Mccarty et al., 2002). After treatment with S-nitrosocaptopril that blocks platelets-CTCs interaction, naked CTCs were exposed to the hostile bloodstream environment increasing their elimination because of FSS and immunosurveillance (Lu et al., 2019).

Although, the effects of FSS on CTCs mechanics are not fully understood, recent works suggest a possible role for FSS-induced EMT enhancing CTCs survival and metastatic capabilities (Choi et al., 2019; Xin et al., 2019; Yu et al., 2021). Upon FSS, CTCs changed their morphology becoming elongated, expressed EMT markers, and reduced F-actin assembly and stiffness (Xin et al., 2019). The resulting soft CTCs displayed
higher chemotherapy resistance (Xin et al., 2019). The Jun N-terminal kinase (JNK) signaling was reported as a mediator between FSS and EMT in CTCs. Flow-activated JNK signaling favors and maintains mesenchymal status that suppresses the proapoptotic p53. Correspondingly, JNK silencing or p53 overexpression decreases CTCs survival (Xin et al., 2020). FSS-dependent nuclear translocation of YAP induces SNAIL1 expression which also triggers EMT (Yu et al., 2021). Interestingly, EMT activation might provide new properties to CTCs such as stemness and the enhanced survival potential usually associated with CSCs or TICs. These properties depend on ROS/nitric oxide (NO) generation and suppression of extracellular signal-regulated kinase (ERK)/glycogen synthase kinase (GSK)3β (Choi et al., 2019). The relationship between FSS and ROS production was further confirmed using a microfluidic chip with five culture areas (for different concentrations) and a shear stress gradient inside each area (Lo et al., 2013).

Upon EMT induction major structural changes in the CTCs cytoskeleton are expected. Cell stiffness is regulated not only by its progression through the cell cycle, but also by malignant transformation (Guck et al., 2005; Hosseini et al., 2021). While it remains unclear whether there is an optimal viscoelastic profile that would allow tumor cells to reach every step of the metastatic cascade, we recently proposed that the key to metastatic success could be their ability to adjust their mechanics to the situation (Gensbittel et al., 2021). Atomic force microscopy used to quantify the rheology (time-dependent deformation under the stress applied) of the tumor cells actin cortex revealed that EMT modulated it in a cell cycle-dependent manner, softening it in interphase and stiffening it in mitosis (Hosseini et al., 2021). Currently, the consensus is that tumor cells are softer and more deformable than healthy cells (Alibert et al., 2017; Kumar and Weaver, 2009) and these differences in cytoskeleton, thus in cell morphology and deformability can be used to isolate CTCs (Guck et al., 2005; Rosendahl et al., 2018; Toepfner et al., 2018). Optical deformability measured using a microfluidic optical stretcher, a two-beam laser trap optimized to serially deform single suspended cells by optically induced surface forces, grants label-free recognition of pathological cells monitoring subtle changes (Guck et al., 2005). Recent advances in microfluidics allow high-throughput real-time deformability cytometry to perform label-free mechanical characterization (Rosendahl et al., 2018), and is likely to provide meaningful CTC mechanics information. In addition, single cell morpho-rheological analysis (MORE) performs the characterization of blood cells in a continuous capillary-like flow, quantifying morphological parameters such as cell shape, size, aggregation, and rheological information leading to accurate identification of CTCs showing a strong potential for clinical application (Toepfner et al., 2018). Considering that different CTC subpopulations derived from diverse cancer types show differential sensitivities to FSS consistent with their biophysical properties (e.g., increased CTCs stiffness lead to increase cell death) (Hope et al., 2021); the biomechanical characterization of specific CTCs might provide a valuable prognostic tool to adapt treatment strategies in real time (Figure 2).

Eventually, CTCs need to arrest inside the vessels and then extravasate, leaving the vasculature, to reach a new niche to form a metastasis. Blood flow modulates both processes of intravascular CTC arrest and endothelial remodeling during extravasation. In vivo imaging in the zebrafish, together with microfluidic characterization of in-flow CTC behavior, revealed that CTCs arrest occurs in vessels with permissible flow profiles, similar to the low perfusion areas where human supratentorial brain metastasis develop preferentially (Follain et al., 2018). Microfluidic devices proved to be a key to dissect CTCs intravascular arrest revealing a two-steps process: first, CTCs stop using low-energy fast-activated adhesion receptors forming transient adhesions; second, high-energy slow-activated adhesion receptors stabilize the adhesions. However, only the receptors involved in stable adhesions are required for extravasation and metastasis (Osmani et al., 2019). In vitro microvascular networks also showed that CTCs glycocalyx, particularly

![Figure 2. Biomechanics and early intravascular behavior of CTCs](image-url)
hyaluronic acid, mediates the adhesion to the endothelium binding CD44 (Offeddu et al., 2021). Regarding the possible role of CTC mechanical properties during intravascular arrest, novel computational models provided a possible explanation to why softer and smaller CTCs adhere more efficiently to the endothelium, whereas stiffer CTCs need 0.05 s longer to adhere which might be explained because of the smaller contact area between the CTC and the vessel (Anvari et al., 2021). These models also shed light into why platelets-coated CTCs arrest faster. Platelets reduce time and distance of CTCs circulation by increasing the forces exerted on the endothelium which leads to stronger adhesions and boosting endothelial VEGF expression promoting extravasation. Moreover, platelets protect CTCs from deformation, improving their survival (Anvari et al., 2021). In vitro assays support the modeling showing that platelets-coated CTCs present higher probability to adhere to endothelial cells under low FSS, as expected, this advantage is loss under high FSS (Burdick and Konstantopoulos, 2004). However, this remains to be demonstrated in vivo.

The extravasation process is also modulated by blood flow, in vivo imaging in the zebrafish showed it can be delayed by impairing flow (Follain et al., 2018). Microfluidic devices used to obtain the transcriptomics profile of endothelial cells cultured under capillary-like FSS revealed an upregulation of vascular endothelial growth factor receptor (VEGFR) signaling. Zebrafish treated with VEGFR inhibitors, including FDA-approved anti-angiogenic Sunitinib, presented impaired flow-mediated endothelial remodeling thus reducing CTCs extravasation (Follain et al., 2021). At the CTCs level, extravasation is enhanced by FSS-dependent matrix metalloproteinases (MMP) upregulation (Qazi et al., 2013) and hyaluronic acid secretion that will bind to endothelial CD44 glyocalyx (Offeddu et al., 2021). Furthermore, degradation of the CTCs glyocalyx and MMP inhibition decreased extravasation (Offeddu et al., 2021; Qazi et al., 2013). These examples highlight the relevance of using microfluidic devices associated with in vivo validation, to dissect biomechanical factors involved in key steps of the metastatic cascade.

PERSPECTIVES

Considering that metastasis is the most important cause of death in cancer patients, a deeper understanding of CTCs, in all aspects, is essential to develop innovative clinical strategies. From a fundamental point of view, providing accurate measurements and description of cellular mechanics during the metastasis cascade will provide a valuable resource to understand better how primary tumors develop life threatening metastases. Therefore, we think that one of the next challenges is the design of microfluidic platforms that allow robust and reproducible usages of isolated CTCs (clustered or not). In addition, relevance of cellular mechanics in human pathology requires validation in more realistic situations such as human samples. One should thus assess cellular mechanics from primary tumor cells derived from patients, at various steps of the disease. Such an approach could (i) confirm that cellular compliance scales with metastasis and (ii) affirm the potential use of cell mechanics as a diagnosis and prognosis tool. Recently, genomic studies have allowed to revisit CTCs’ identity and revealed that CTCs display plastic hybrid-EMT states, which contribute to their adaptability, survival, and ultimate metastatic success. Classically, the characterization of CTCs based on epithelial markers biases the subpopulations isolated for study and thus our understanding of their properties. Similarly, because metastatic potential scales with the ability that CTCs have to cluster, significant efforts should be put towards the development of efficient isolation methods that not only enrich this specific CTC subpopulation, but also preserve their physical/structural integrity allowing deeper characterization. The development of new microfluidic-based CTCs isolation methodologies represents an important breakthrough to achieve a complete characterization of single- and clustered-CTCs. Furthermore, the need to rely on different CTC properties to bypass the EMT-status bias, highlight the interest of biophysical properties. Changes in the mechanical properties of cells often correlate with their pathophysiological states. However, clinical relevance requires measurement throughputs of > several 1000 cells in a few seconds. Such throughput has recently been achieved using real-time deformability cytometry (RT-DC) (Otto et al., 2015) and paves the way for exploiting mechanical phenotyping for cancer diagnostic applications (Figure 1E). In conclusion, the creation of high throughput microfluidic-based and mechanical properties-based isolation devices to collect the different CTCs subpopulation; together with the design of tailored CTC cluster isolation methods, will bring us closer to winning the battle against metastasis.

ACKNOWLEDGMENTS

We thank all members of J.G. Goetz’s team for their constant discussions on this particular topic. J.G. Goetz is the coordinator of the NANOTUMOR Consortium, a program from ITMO Cancer of AVIESAN
(Alliance Nationale pour les Sciences de la Vie et de la Santé, National Alliance for Life Sciences & Health) within the framework of the Cancer Plan (France). We are grateful to Jochen Guck and his group (Max Planck Institute for the Science of Light, Erlangen) for constant discussions. Work and people in the lab of J.G. Goetz is mostly supported by the INCa (Institut National Du Cancer, French National Cancer Institute), charities (La Ligue contre le Cancer, ARC (Association pour la Recherche contre le Cancer), FRM (Fondation pour la Recherche Médicale), the National Plan Cancer Initiative, the Region Est, INSERM (Institut national de la santé et de la recherche médicale), and the University of Strasbourg. We are also thankful to recent donors (Rohan Athletisme Saverne) for supporting our work.

DECLARATION OF INTEREST

The authors declare no competing interests.

REFERENCES

Aceto, N., Bardia, A., Miyamoto, D.T., Donaldson, M.C., Wittner, B.S., Spencer, J.A., Yu, M., Pely, A., Emonts, A., Zhu, H., et al. (2014). Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110–1122.

Agerbæk, M., Bang-Christensen, S.R., Yang, M.H., Clausen, T.M., Pereira, M.A., Sharma, S., Dittev, S.B., Nielsen, M.A., Choudhury, S., Gustavsson, T., et al. (2018). The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat. Commun. 9, 3279.

Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U S A 100, 3983–3988.

Alibert, C., Goud, B., and Manneville, J.B. (2017). Are cancer cells really softer than normal cells? Biol. Cell 109, 167–189.

Alix-Panabieres, C., Brouillet, J.P., Fabbro, M., Yssel, H., Rousset, T., Maudelonde, T., Choquet-Alibert, C., Goud, B., and Manneville, J.B. (2017). Are cancer cells really softer than normal cells? Biol. Cell 109, 167–189.

Anvari, S., Osei, E., and Mafteo, N. (2021). Interactions of platelets with circulating tumor cells contribute to cancer metastasis. Sci. Rep. 11, 15477.

Ao, Z., Shah, S.H., Machlin, L.M., Parajuli, R., Miller, P.C., Rawal, S., Williams, A.J., Cote, R.J., Lippman, M.E., Datar, R.H., et al. (2015). Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res. 75, 4681–4687.

Au, S.H., Storey, B.D., Moore, J.C., Tang, Q., Chen, Y.-L., Javid, S., Sarigol, A.F., Sullivan, R., Madden, M.W., Koecke, R., et al. (2016). Clusters of circulating tumor cells traverse capillary-sized vessels. Proc. Natl. Acad. Sci. U S A 113, 4947–4952.

Baccelli, I., Schneeveiss, A., Riether, S., Stenzinger, A., Schillert, A., Vogel, V., Klein, C., Sani, M., Bauerle, T., Wallwiener, M., et al. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31, 539–544.

Bankó, P., Lee, S.Y., Nagygyörgy, V., Zrínyi, M., Chae, C.H., Cho, D.H., and Telekes, A. (2019). Technologies for circulating tumor cell separation from whole blood. J. Hematol. Oncol. 12, 1–20.

Barnes, J.M., Nauseef, J.T., and Henry, M.D. (2012). Resistance to fluid shear stress is a conserved biophysical property of malignant cells. PLoS One 7, e50973.

Beerling, E., Seinsma, D., de Wit, E., Kester, L., van der Velden, D., Maynard, C., Schafer, R., van Diest, P., Voest, E., van Oudenaarden, A., et al. (2016). Plasticity between epithelial and mesenchymal states unlink EMT from metastasis-enhancing stem cell capacity. Cell Rep. 14, 2281–2288.

Best, M.G., Sol, N., Kooi, I., Tannous, J., Westerman, B.A., Rustenburg, F., Schellen, P., Verschueren, H., Post, E., Koster, J., et al. (2015). RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multi-class, and molecular pathway cancer diagnostics. Cancer Cell 28, 666–676.

Brown, M., Assen, F.P., Leitner, A., Abe, J., Schachner, H., Asfour, G., Bago-Horvat, Z., Stein, J.V., Uhrin, P., Suti, M., et al. (2018). Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 359, 1408–1411.

Burdick, M.M., and Konstantopoulos, K. (2004). Platelet-induced enhancement of SL174T colon carcinoma and THP-1 monocytic cell adhesion to vascular endothelium under flow. Am. J. Physiol. 287, C539–C547.

Cameron, M.D., Schmidt, E.E., Kerkvliet, N., Nadkarni, K.V., Morris, V.L., Groom, A.C., Chambers, A.F., and MacDonald, I.C. (2000). Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60, 2541–2546.

Caramel, J., Papadoyorgakis, E., Hill, L., Browne, G.J., Richard, G., Wierinckx, A., Saldanha, G., Osborne, J., Hutchinson, P., Tse, G., et al. (2013). A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 24, 466–480.

Casasent, A.K., Schack, A., Gao, R., Mercier-Bernstad, F., Edgerton, M.E., and Navin, N.E. (2018). Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell 172, 205–210 e12.

Chambers, A.F., Groom, A.C., and MacDonald, I.C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563–572.

Chen, D.S., and Meliman, I. (2017). Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330.

Chen, M.B., Whisler, J.A., Jeon, J.S., and Kamrn, R.D. (2013). Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. Integr. Biol. Quant. Biosci. Nano Macro 5, 1262–1271.

Chen, M.B., Hajal, C., Benjamin, D.C., Yu, C., Azizgolshani, H., Hynes, R.O., and Kamrn, R.D. (2018). Inflamed neutrophils sequestered at entrapped tumor cells via chemotactic confinement promote tumor cell extravasation. Proc Natl Acad Sci U S A 115, 7022–7027.

Cheung, K.J., Padmanaban, V., Silvestri, V., Schipper, K., Cohen, J.D., Fairchild, A.N., Gorin, M.A., Verdone, J.E., Pinta, K.J., Bader, J.S., et al. (2016). Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl. Acad. Sci. U S A 113, E854–E863.

Choi, H.Y., Yang, G.-M., Dayem, A.A., Saha, S.K., Kim, K., Yoo, Y., Hong, K., Kim, J.-H., Yee, C., Lee, K.-M., et al. (2019). Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3β activities. Breast Cancer Res. 21, 6.

Choi, J.W., Kim, J.K., Yang, Y.J., Kim, P., K.-H., and Yun, S.H. (2015). Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells. Cancer Res. 75, 4474–4482.

Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., and Ferri, L. (2013). Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. 123, 3446–3458.

Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., Reuben, J.M., Doyle, G.V., Allard, W.J., Terstappen, L.W.M.M., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781–791.

Dixon, J.B., Greener, S.T., Gashee, A.A., Cote, G.L., Moore, J.E., and Zawieja, D.C. (2006). Lymph flow, shear stress, and lymphocyte velocity in rat...
mesenteric prenodal lymphatics. Microcirculation 13, 597–610.

Follain, G., Osmani, N., Azevedo, A.S., Allio, G., Mercier, L., Karreman, M.A., Soelecki, G., Garcia Leon, M.J., Lefebvre, O., Fekonja, N., et al. (2018). Hemodynamic forces tune the arrest, adhesion, and extravasation of circulating tumor cells. Dev. Cell 45, 33–52 e12.

Follain, G., Herrmann, D., Harlepp, S., Hyenne, V., Osmani, N., Warren, S.C., Timpson, P., and Goetz, J.G. (2020). Fluids and their mechanics in tumour transit: shaping metastasis. Nat. Rev. Cancer 20, 107–124.

Follain, G., Osmani, N., Gensbittel, V., Asokan, N., Lamicoli, A., Mercier, L., Garcia-Leon, M.J., Busnelli, J., Pichot, A., Paul, N., et al. (2021). Impairing flow-mediated endothelial remodeling reduces extravasation of tumor cells. Sci. Rep. 17, 13144.

Ganesh, K., and Massagué, J. (2021). Targeting metastatic cancer. Nat. Med. 27, 34–44.

Gao, Y., Wu, M., Lin, Y., and Xu, J. (2020). Acoustic microfluidic separation techniques and bioapplications: a review. Micromachines 11, 921.

Gascogne, P.R.C., and Shin, S. (2014). Isolation of circulating tumor cells by dielectrophoresis. Cancers 6, 545–579.

Gast, C.E., Silk, A.D., Zerour, L., Riegler, L., Buikwe, F., Gustafson, K.T., Parapilly, M.S., Roh-Johnson, M., Goodman, J.R., Olson, B., et al. (2018). Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci. Adv. 4, 7828–7840.

Gensbittel, V., Krater, M., Harlepp, S., Busnelli, I., Guck, J., and Goetz, J.G. (2021). Mechanical adaptability of tumor cells in metastasis. Dev. Cell 56, 164–179.

Ghoroghi, S., Mary, B., Asokan, N., Goetz, J.G., and Hyenne, V. (2021). Tumor extracellular vesicles drive metastasis (it’s a long way from home). FASEB J. 39, 930–943.

Giampieri, S., Manning, C., Hooper, S., Jones, L., Dominick, A.P., Adler, G., and Baskaran, R. (2019). Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98–112 e14.

Guck, J., Schinkinger, S., Lincoln, B., Wottawah, F., Ebert, S., Romeyke, M., Lenz, D., Erickson, H.M., Ananthakrishnan, R., Mitchell, D., et al. (2019). Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence. Biophys. J. 88, 3689.

Hannahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674.

Haney, A.S., Anwert, E.N., Entenberg, D., Wang, Y., Guo, P., Quan, B.Z., Oktay, M.H., Pollard, J.W., Jones, J.G., and Condeelis, J.S. (2015). Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 5, 932–943.

Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valaders, A., Nagi, C., Girius, N., Davis, R.J., et al. (2016). Mechanism of early dissemination and metastasis in Her2 + mammary cancer. Nature 540, 588–592.

Headley, M.B., Bins, A., Ngo, A., Roberts, E.W., Looney, M.R., Gerard, A., and Krummel, M.F. (2016). Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 531, 513.

Heeke, S., Mograbi, B., Alix-Panabières, C., and Hofman, P. (2019). Never travel alone: the crosstalk of circulating tumor cells and the blood microenvironment. Cells 8, 714.

Hope, J.M., Berti, M.R., Dombroski, J.A., clinic, A.B., Perelis, R.S., David Merrymon, W., and King, M.R. (2021). Circulating prostate cancer cells have differential resistance to fluid shear stress-induced cell death. J. Cell Sci. 134, jcs251470.

Hosseini, H., Obradovic, M.M.S., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Mareck, M., et al. (2016). Early dissemination seeds metastasis in breast cancer. Nature 540, 552–558.

Hosseini, K., Frenzel, A., and Fischer-Friedrich, E. (2021). EMT changes actin cortex rheology in a cell-cycle-dependent manner. Biophys. J. 120, 3516–3526.

Hou, J.-M., Krebs, M.G., Lancashire, L., Sloane, R., Backen, A., Swain, R.K., Priest, J.L.C., Greystoke, A., Zhou, C., Morris, K., et al. (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30, 525–532.

Hu, Z., and Curtis, C. (2020). Looking backward in time to define the chronology of metastasis. Nat. Commun. 11, 3213.

Huang, L., Ji, H., Yin, L., Niu, X., Wang, Y., Liu, Y., Xuan, Q., Li, L., Zhang, H., Zhou, X., et al. (2019). High expression of plakoglobin promotes metastasis in invasive micropapillary carcinoma of the breast via tumor cluster formation. J. Cancer 10, 2800–2810.

Huang, Q., Li, S., Hu, X., Sun, M., Wu, Q., Dai, H., Tan, Y., Sun, F., Wang, C., Rong, X., et al. (2020). Shear stress activates AT06H via autocrine VEGF-ErbB receptor signaling to control tumor viability and metastasis. Methods 101, 47–55.

Huang, S., Patel, D.B., et al. (2019). Homophilic FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells. Cytom. Part J. Int. Soc. Anal. Cytol. 93, 1251–1254.

Lee, Y., Guan, G., and Bhagat, A.A. (2018). CreaCell® FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells. Cytom. Part J. Int. Soc. Anal. Cytol. 93, 1251–1254.

Lei, K.F. (2020). A review on microdevices for isolating circulating tumor cells. Micromachines 11, 531.

Li, C.-F., Chen, Y.-H., Hsu, W.-H., Wu, L.-C., Lan, H.-Y., Hsu, D.-S., Tai, S.-K., Chang, Y.-C., and Yang, M.-H. (2019). Snail-induced claudin-11 prompts collective migration for tumour progression. Nat Cell Biol. 21, 251–262.

Liu, X., Tafta, R., Kawaguchi, M., Chang, Y.-F., Chen, W., Entenberg, D., Zhang, Y., Genemana, L., Huang, S., Patel, D.B., et al. (2019). Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discov. 9, 96–113.

Lo, K.Y., Zhu, Y., Tsai, H.F., and Sun, Y.S. (2013). Effects of shear stresses and antioxidant
concentrations on the production of reactive oxygen species in lung cancer cells. Biomicrofluidics 7, 64108.

Lopes, C., Piairo, P., Chicharo, A., Absalde-Cela, S., Piñes, L.R., Corredorre, P., Alves, P., Muñelo-Romay, L., Costa, L., and Diéguez, L. (2021). Her2 expression in circulating tumour cells isolated from metastatic breast cancer patients using a size-based microfluidic device. Cancers 13, 4446.

Lu, Y., Lian, S., Ye, Y., Yu, T., Liang, H., Cheng, Y., Xie, J., Zhu, Y., Xie, X., Yu, S., et al. (2019). S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells. Pharmacol. Res. 139, 535–549.

Luzzi, K.J., MacDonald, I.C., Schmidt, E.E., Kerklé, N., Morris, V.L., Chambers, A.F., and Groom, A.C. (1998). Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153, 865–873.

Maeshiro, M., Shinriki, S., Liu, R., Nakachi, K., Komohara, Y., Fujiwara, Y., Ohtsubo, K., Yoshida, M., Maeshiro, M., Shinriki, S., Liu, R., Nakachi, Y., et al. (2021). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239.

Ocana, O.H., Córrcoles, R., Fabra, A., Moreno-Bueno, G., Adocho, H., Vega, S., Barraló-Gimeno, A., Cano, A., and Nieto, M.A. (2012). Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724.

Offeddu, G.S., Hajal, C., Foley, C.R., Wan, Z., Ibrahim, L., Coughlin, M.F., and Kamrn, R.D. (2021). The cancer glycoalkalizes intravascular adhesion and extravasation during metastatic dissemination. Commun. Biol. 4, 255.

Ortiz-Otero, N., Clinic, A.B., Hope, J., Wang, W., Reinhardt-King, C.A., King, M.R., Ortiz-Otero, N., Clinic, A.B., Hope, J., Wang, W., et al. (2020). Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression. Oncotarget 11, 1037–1050.

Osmani, N., Follain, G., García León, M.J., Lefebvre, O., Busnelli, I., Lamlac, A., Harlepp, S., and Goetz, J.G. (2019). Metastatic tumor cells exploit their adhesion repertoire to counteract shear forces during intravascular arrest. Cell Rep. 28, 2491–2500.e5.

Otto, O., Rosendahl, P., Mietke, A., Golffier, S., Herold, C., Kluge, D., Girardo, S., Pagliara, S., Eskenyong A., Jacobi, A., et al. (2015). Real-time deformability cytometry: on-the-fly cell mechanical phenotyping. Nat. Methods 12, 199–202.

Ozukum, E., Shah, A.M., Cicilliano, J.C., Emmink, B.L., Miyamoto, D.T., Brachtel, E., Yu, M., Chen, P.I., Morgan, B., Trautwein, J., et al. (2016). Inertial focusing for tumor antigen–dependent and –independent sorting of rare circulating tumor cells. Sci. Transl. Med. 5, 179ra47.

Padmanabhan, V., Krol, I., Suahil, Y., Sazzerbo, B.M., Aceto, N., Nader, J.S., and Ewald, A.J. (2019). E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573, 439–444.

Palumbo, J.S., Talmage, K.E., Massari, J.V., La Jeunesse, C.M., Flick, M.J., Kombnick, K.W., Jiroušková, M., and Degen, J.L. (2005). Platelets and fibrinogen increase metastatic potential by impeding normal killer cell-mediated elimination of tumor cells. Blood 105, 178–185.

Pasolleti, C., Miao, J., Dole, E.M., Darga, E.P., Repollet, M.I., Doyle, G.V., Gralow, J.R., Hortobagyi, G.N., Smerage, J.B., Barlow, W.E., et al. (2019). Circulating tumor cell clusters in patients with metastatic breast cancer: a SWOG S0500 translational medicine study. Clin. Cancer Res. 25, 6089–6097.

Papa, A.L., Jiang, A., Korn, N., Chen, M.B., Langan, E.T., Waterhouse, A., Nash, E., Caroff, J., Graveline, A., Vernet, A., et al. (2019). Platelet decays inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci. Transl. Med. 11, eaau5891.

Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeul, A., Brown, D., Moers, V., Lemaire, S., et al. (2019). Identification of the tumour transition states occurring during EMT. Nature 556, 463–468.

Pereira, E.R., Kedrin, D., Seano, G., Gautier, O., Meijer, E.F.J., Jones, D., Chin, S.-M., Kitahara, S., Bouts, E.M., Chang, J., et al. (2018). Lympne node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 359, 1403–1407.

Pignatelli, J., Bravo-Cordero, J.J., Roh-Johnson, M., Gandhi, S.J., Wang, X.-Ch., Eddy, R.J., Xue, A., Singer, R.H., Hodgson, L., et al. (2016). Macrophage-dependent tumor cell transendothelial migration is mediated by Notch/ΔN-Meaf1-mediated podocytod formation. Sci. Rep. 6, 37874.

Pikberg, C.F., Raba, K., Muller, F., Behrens, B., Honisch, E., Niederaeher, D., Neubauer, B., Fehm, T., Goering, W., Schulz, W.A., et al. (2017). Analysis of DNA methylation in single circulating tumor cells. Oncogene 36, 3223–3231.

Placke, T., Orgel, M., Schaller, M., Jung, G., Ramnisse, H.-G., Kopp, H.-G., and Salih, H.R. (2012). Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 72, 440–448.

Powell, A.A., Talasaz, A.A.H., Zhang, H., Coram, M.A., Reddy, A., Deng, G., Tell, M.L., Advani, R.H., Carlson, R.W., Moolick, J.A., et al. (2012). Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 7, e33768.

Qazi, H., Palomino, R., Shi, Z.D., Munn, L.L., and Tarbell, J.M. (2013). Cancer cell glycoalkalizes mediates mechanotransduction and flow-regulated invasion. Integr. Biol. U. K. 5, 1334–1343.

Regni, S., Fu, A., and Luo, K.C.G. (2017). High shear stresses under exercise condition destroy circulating tumor cells in a microfluidic system. Sci. Rep. 7, 39975.

Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., VonHederlie, R.H., et al. (2012). EMT and dissemination predict pancreatic tumor formation. Cell 148, 349–361.

Ribeiro-Samy, S., Oliveira, M.I., Pereira-Veiga, T., Muñelo-Romay, L., Carvalho, G., Gaspar, J., Freitas, P.P., López-López, R., Costa, C., and Diéguez, L. (2019). Fast and efficient microfluidic cell filter for isolation of circulating tumor cells from unprocessed whole blood of colorectal cancer patients. Sci. Rep. 9, 8032.

Rosendahl, P., Pliak, K., Jacobi, A., Kraeter, M., Toepfner, N., Otto, O., Herold, C., Winzi, M., et al. (2017). High shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors. New J. Phys. 15, 015008.

Mitchell, M.J., Denis, C., Chan, M.F., Wang, Z., Lammerding, J., and King, M.R. (2015). Lamin A/C deficiency reduces circulating tumor cell resistance to fluid shear stress. Am. J. Physiol. Cell Physiol. 309, C736–C746. https://doi.org/10.1152/ajpcell.00050.2015.

Monteran, L., and Erez, N. (2019). The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front. Immunol. 10, 1835.

Moose, D.L., Krog, B.L., Kim, T.H., Zhao, L., Williams-Perez, S., Burke, G., Rhodes, L., Vanneste, M., Braeheny, P., Milhem, M., et al. (2020). Cancer cells resist mechanical destruction in circulation via Rhoadactomysin-dependent mechano-adaptation. Cell Rep. 30, 3864–3874.e6.

Nagrath, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L., Smith, M.R., Kwas, E.L., Digumarthy, S., Muzikansky, A., et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1233–1239.

Nagashima, M., Shinriki, S., Liu, R., Nakachi, K., Komohara, Y., Fujiwara, Y., Ohtsubo, K., Yoshida, M., Yabu, Y., and Nakachi, Y. (2019). Separation System—a versatile liquid biopsy adaptive to fluid shear stress. Sci. Rep. 9, 153.
Herbig, M. Ge, Y., et al. (2018). Real-time fluorescence and deformability cytometry. Nat. Methods 15, 355–358.

San Juan, B.P., Garcia-Leon, M.J., Rangel, L., Goetz, J.G., and Chaffer, C.L. (2019). The complexities of metastasis. Cancers 11, 1573.

Sariaglu, A.F., Aceto, N., Kojic, N., Donaldson, M.C., Zenali, M., Hamza, E., Engstrom, A., Zhu, H., Sundaresan, T.K., Miyamoto, D.T., et al. (2015). A microfluidic device for label-free, physical capturing of circulating tumor cell clusters. Nat. Methods 12, 685–691.

Saucedo-Zeni, N., Mieves, S., Niestroj, R., Gasiorowski, L., Murawa, D., Nowacyzk, P., Tomassi, T., Weber, E., Dworacki, G., Morgenthaler, N.G., et al. (2012). A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int. J. Oncol. 41, 1241–1250.

Schumacher, D., Strilic, B., Sivaraj, K.K., Working, N., and Offermanns, S. (2013). Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24, 130–137.

Simeonov, K.P., Bynm, C.N., Clark, M.L., Norgard, R.J., Martin, B., Stanger, B.Z., Shendure, J., McKenna, A., and Lengner, C.J. (2021). Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150–1162.e9.

Spicer, J.D., McDonald, B., Cools-Lartigue, J.J., Chow, S.C., Giannias, B., Kubes, P., and Ferri, L.E. (2012). Neutrophils promote liver metastasis via Mac-1–mediated interactions with circulating tumor cells. Cancer Res. 72, 3919–3927.

Spiegel, A., Brooks, M.W., Houshyar, S., Reinhardt, F., Ardonino, M., Fessler, E., Chen, M.B., Krall, J.A., Decock, J., Zervantonakis, I.K., et al. (2016). Neutrophils suppress intraluminal NK-cell–mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov. 6, 630–649.

Stott, S.L., Hsu, C.H., Tsukrov, D.I., Yu, M., Miyamoto, D.T., Wallman, B.A., Michael Rothenberg, S., Shah, A.M., Smas, M.E., Korir, G.K., et al. (2010). Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. U S A 107, 18392–18397.

Suhail, Y., Cain, M.P., Vanaja, K., Kurywchak, P.A., Levchenko, A., Kalluri, R., and Khshitiz (2019). Systems biology of cancer metastasis. Cell Syst 9, 109–127.

Szczepańska, B.M., Castro-Giner, F., Vetter, M., Krol, I., Gkountela, S., Landin, J., Scheidmann, M.C., Donato, C., Scherrer, R., Singer, J., et al. (2019). Neutrophils escort circulating tumor cells to enable cell cycle progression. Nature 566, 553–557.